1. Abnormal transaminase and lipid profiles in coexisting diseases in patients with fatty liver: a population study in Sichuan.
- Author
-
Jiang W, Liu CH, Wu D, Wang YJ, and Tang H
- Subjects
- Adult, Biomarkers blood, China epidemiology, Clinical Enzyme Tests, Comorbidity, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 diagnosis, Diabetes Mellitus, Type 2 epidemiology, Fatty Liver diagnosis, Female, Hepatitis B blood, Hepatitis B diagnosis, Hepatitis B epidemiology, Humans, Liver Function Tests, Male, Metabolic Syndrome blood, Metabolic Syndrome diagnosis, Metabolic Syndrome epidemiology, Middle Aged, Prevalence, Risk Assessment, Risk Factors, Thyroid Diseases blood, Thyroid Diseases diagnosis, Thyroid Diseases epidemiology, Alanine Transaminase blood, Aspartate Aminotransferases blood, Fatty Liver blood, Fatty Liver epidemiology, Lipids blood
- Abstract
Among chronic liver diseases, fatty liver has the highest incidence worldwide. Coexistence of fatty liver and other chronic diseases, such as diabetes, hepatitis B virus (HBV) and Helicobacter pylori (Hp) infection, is common in clinical practice. The present study was conducted to analyze the prevalence and association of coexisting diseases in patients with fatty liver and to investigate how coexisting diseases contribute to abnormal transaminase and lipid profiles. We enrolled participants who were diagnosed with fatty liver via ultrasound in the physical examination center of West China Hospital. Multivariable logistic regression was used to determine the adjusted odds ratios (ORs). We found that 23.6% of patients who underwent physical examinations were diagnosed with fatty liver. These patients had higher risks of metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM), and hypertension and a lower risk of HBV infection. The risks of Hp infection and hyperthyroidism did not statistically differ. When fatty liver coexisted with T2DM, MetS and thyroid dysfunction, it conferred a higher risk of elevated transaminase. Fatty liver was positively correlated with triglycerides, cholesterol and low-density lipoprotein cholesterol (LDL-C) and negatively correlated with HBV; thus, HBV had a neutralizing effect on lipid metabolism when coexisting with fatty liver. In conclusion, patients with fatty liver that coexists with T2DM, MetS and thyroid dysfunction are more prone to elevated transaminase levels. Patients with both fatty liver and HBV may experience a neutralizing effect on their lipid metabolism. Thus, lipid alterations should be monitored in these patients during antiviral treatment for HBV., (© 2021 The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF